Sunmax Biotechnology Co Ltd Net Assets

Latest as of September 2025: NT$1.44 Billion TWD ≈ $45.51 Million USD

Sunmax Biotechnology Co Ltd net assets. Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has net assets worth NT$1.44 Billion TWD (≈ $45.51 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.90 Billion ≈ $59.82 Million USD) and total liabilities (NT$454.35 Million ≈ $14.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Sunmax Biotechnology Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets NT$1.44 Billion
% of Total Assets 76.07%
Annual Growth Rate 11.71%
5-Year Change 70.2%
10-Year Change N/A
Growth Volatility 10.73

Net Assets of Sunmax Biotechnology Co Ltd (2015–2024)

Net assets of Sunmax Biotechnology Co Ltd from 2015 to 2024. This chart illustrates how Sunmax Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. See Sunmax Biotechnology Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Annual Net Assets for Sunmax Biotechnology Co Ltd (2015–2024)

The table below shows the annual net assets of Sunmax Biotechnology Co Ltd from 2015 to 2024. For live market cap and overall valuation, see how much is Sunmax Biotechnology Co Ltd worth.

Year Net Assets Change
2024-12-31 NT$1.51 Billion
≈ $47.66 Million
+6.09%
2023-12-31 NT$1.43 Billion
≈ $44.93 Million
+7.60%
2022-12-31 NT$1.33 Billion
≈ $41.75 Million
+29.48%
2021-12-31 NT$1.02 Billion
≈ $32.25 Million
+15.16%
2020-12-31 NT$888.84 Million
≈ $28.00 Million
+31.32%
2019-12-31 NT$676.83 Million
≈ $21.32 Million
+4.45%
2018-12-31 NT$648.01 Million
≈ $20.42 Million
+13.15%
2017-12-31 NT$572.70 Million
≈ $18.04 Million
+3.14%
2016-12-31 NT$555.29 Million
≈ $17.49 Million
-0.53%
2015-12-31 NT$558.24 Million
≈ $17.59 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Sunmax Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 79710300000.0% over the analyzed period, indicating profitable operations and earnings retention.

Sunmax Biotechnology Co Ltd Net Assets Breakdown (December 2024)

Sunmax Biotechnology Co Ltd net assets breakdown by equity component as of December 2024.

Component Amount Percentage
Retained Earnings NT$768.12 Million 50.77%
Other Components NT$744.72 Million 49.23%
Total Equity NT$1.51 Billion 100.00%

Sunmax Biotechnology Co Ltd Competitors by Market Cap

The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their market capitalization.

Company Market Cap
Anhui Korrun Co Ltd
SHE:300577
$680.50 Million
Suqian Unitech Corp. Ltd. Cl A
SHG:603065
$680.52 Million
Shanghai Yct Electronics Group Co.Ltd
SHE:301099
$680.55 Million
Sapphire Foods India Limited
NSE:SAPPHIRE
$680.70 Million
Hainan Shennong Technology Co Ltd
SHE:300189
$680.29 Million
Beijing Utour International Travel Service Co Ltd
SHE:002707
$680.18 Million
Charter Hall Social Infrastructure REIT
AU:CQE
$680.09 Million
CERES POWER HLDGS
F:CFJ
$679.96 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sunmax Biotechnology Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,426,046,000 to 1,512,838,000, a change of 86,792,000 (6.1%).
  • Net income of 679,405,000 contributed positively to equity growth.
  • Dividend payments of 599,093,000 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income NT$679.40 Million +44.91%
Dividends Paid NT$599.09 Million -39.6%
Other Changes NT$6.48 Million +0.43%
Total Change NT$- 6.09%

Book Value vs Market Value Analysis

This analysis compares Sunmax Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 14.27x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 37.39x to 14.27x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 NT$10.60 NT$396.50 x
2018-12-31 NT$11.90 NT$396.50 x
2019-12-31 NT$12.43 NT$396.50 x
2020-12-31 NT$16.30 NT$396.50 x
2021-12-31 NT$18.77 NT$396.50 x
2022-12-31 NT$24.30 NT$396.50 x
2023-12-31 NT$26.15 NT$396.50 x
2024-12-31 NT$27.78 NT$396.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sunmax Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 44.91%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 71.58%
  • • Asset Turnover: 0.51x
  • • Equity Multiplier: 1.22x
  • Recent ROE (44.91%) is above the historical average (20.15%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 -7.91% -39.55% 0.19x 1.08x NT$-99.99 Million
2016 0.31% 1.12% 0.26x 1.08x NT$-53.79 Million
2017 2.89% 8.70% 0.29x 1.15x NT$-40.74 Million
2018 11.52% 24.55% 0.40x 1.17x NT$9.86 Million
2019 14.84% 16.91% 0.53x 1.64x NT$32.76 Million
2020 26.79% 27.82% 0.63x 1.53x NT$149.19 Million
2021 24.00% 23.72% 0.70x 1.45x NT$143.28 Million
2022 40.28% 38.13% 0.78x 1.35x NT$401.30 Million
2023 43.88% 37.05% 0.78x 1.51x NT$483.10 Million
2024 44.91% 71.58% 0.51x 1.22x NT$528.12 Million

Industry Comparison

This section compares Sunmax Biotechnology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,874,178,200
  • Average return on equity (ROE) among peers: 0.02%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sunmax Biotechnology Co Ltd (4728) NT$1.44 Billion -7.91% 0.31x $680.35 Million
Apex Biotechnology Corp (1733) $1.64 Billion 5.79% 0.55x $88.17 Million
Sinphar Pharmaceutical Co Ltd (1734) $3.14 Billion -0.91% 0.95x $166.28 Million
Panion & BF Biotech Inc (1760) $301.62 Million -13.03% 1.86x $107.10 Million
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) $837.53 Million 14.62% 1.72x $65.79 Million
SYN-Tech Chem & Pharm Co Ltd (1777) $2.59 Billion 10.10% 0.14x $101.15 Million
Level Biotechnology (3118) $522.28 Million 13.08% 0.40x $29.04 Million
GenMont Biotech Inc (3164) $1.28 Billion -18.44% 0.10x $41.87 Million
Medigen Biotechnology (3176) $6.43 Billion -0.82% 0.28x $116.09 Million
Sagittarius Life Science (3205) $588.38 Million -12.60% 0.26x $80.97 Million
Genovate Biotechnology Co Ltd (4130) $1.41 Billion 2.42% 0.12x $115.03 Million

About Sunmax Biotechnology Co Ltd

TWO:4728 Taiwan Biotechnology
Market Cap
$680.35 Million
NT$21.59 Billion TWD
Market Cap Rank
#10019 Global
#304 in Taiwan
Share Price
NT$396.50
Change (1 day)
+4.62%
52-Week Range
NT$373.00 - NT$409.00
All Time High
NT$494.50
About

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.